secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0001193125-24-095472
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora's NMRA-266 Phase 1 placed on clinical hold by FDA after rabbit convulsion data
--------------------------------------------------------------------------------

- FDA placed clinical hold on NMRA-266 Phase 1 trial due to preclinical convulsions in rabbits.
- Approximately 30 participants dosed in study; no convulsions observed in any participant.
- Company working with FDA to evaluate resolving the hold; prior guidance on NMRA-266 withdrawn.
- NMRA-266 is an M4 muscarinic receptor PAM, part of Neumora's M4 PAM franchise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312524095472/0001193125-24-095472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312524095472/d805556d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-095472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer